Kurzrock R - Search Results

1

Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.

Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS. Herbst RS, et al. Among authors: kurzrock r. J Clin Oncol. 2010 Jun 10;28(17):2839-46. doi: 10.1200/JCO.2009.25.1991. Epub 2010 May 10. J Clin Oncol. 2010. PMID: 20458040 Clinical Trial.

2

Phase I study of recombinant human interleukin-3 in patients with bone marrow failure.

Kurzrock R, Talpaz M, Estrov Z, Rosenblum MG, Gutterman JU. Kurzrock R, et al. J Clin Oncol. 1991 Jul;9(7):1241-50. doi: 10.1200/JCO.1991.9.7.1241. J Clin Oncol. 1991. PMID: 2045865 Clinical Trial.

3

Phase I study of a combination of recombinant tumor necrosis factor-alpha and recombinant interferon-gamma in cancer patients.

Kurzrock R, Feinberg B, Talpaz M, Saks S, Gutterman JU. Kurzrock R, et al. J Interferon Res. 1989 Aug;9(4):435-44. doi: 10.1089/jir.1989.9.435. J Interferon Res. 1989. PMID: 2502584

4

Phase I study of multiple dose intramuscularly administered recombinant gamma interferon.

Kurzrock R, Quesada JR, Talpaz M, Hersh EM, Reuben JM, Sherwin SA, Gutterman JU. Kurzrock R, et al. J Clin Oncol. 1986 Jul;4(7):1101-9. doi: 10.1200/JCO.1986.4.7.1101. J Clin Oncol. 1986. PMID: 3088221

5

Phase I study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients.

Kurzrock R, Rosenblum MG, Quesada JR, Sherwin SA, Itri LM, Gutterman JU. Kurzrock R, et al. J Clin Oncol. 1986 Nov;4(11):1677-83. doi: 10.1200/JCO.1986.4.11.1677. J Clin Oncol. 1986. PMID: 3095504

6

A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients.

Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman JU. Feinberg B, et al. Among authors: kurzrock r. J Clin Oncol. 1988 Aug;6(8):1328-34. doi: 10.1200/JCO.1988.6.8.1328. J Clin Oncol. 1988. PMID: 3411344

7

Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma.

Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R. Seymour JF, et al. Among authors: kurzrock r. J Clin Oncol. 1995 Mar;13(3):575-82. doi: 10.1200/JCO.1995.13.3.575. J Clin Oncol. 1995. PMID: 7884418

8

All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome.

Kurzrock R, Estey E, Talpaz M. Kurzrock R, et al. J Clin Oncol. 1993 Aug;11(8):1489-95. doi: 10.1200/JCO.1993.11.8.1489. J Clin Oncol. 1993. PMID: 8336187

9

Second cancer risk in hairy cell leukemia: analysis of 350 patients.

Kurzrock R, Strom SS, Estey E, O'Brien S, Keating MJ, Jiang H, Adams T, Talpaz M. Kurzrock R, et al. J Clin Oncol. 1997 May;15(5):1803-10. doi: 10.1200/JCO.1997.15.5.1803. J Clin Oncol. 1997. PMID: 9164188

10

RAS and leukemia: from basic mechanisms to gene-directed therapy.

Beaupre DM, Kurzrock R. Beaupre DM, et al. Among authors: kurzrock r. J Clin Oncol. 1999 Mar;17(3):1071-9. doi: 10.1200/JCO.1999.17.3.1071. J Clin Oncol. 1999. PMID: 10071302 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

984 results

Search Page